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Abstract
Previous work from our labs has indicated that a tropane analog of haloperidol with potent D2
binding but designed to avoid the formation of MPP+-like metabolites, such as 4-(4-
chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)pyridin-1-ium (BCPP+) still produced catalepsy,
suggesting a strong role for the D2 receptor in the production of catalepsy in rats, and hence EPS
in humans. This study tested the hypothesis that further modifications of the tropane analog to
produce compounds with less potent binding to the D2 receptor than haloperidol, would produce
less catalepsy. These tests have now revealed that while haloperidol produced maximum
catalepsy, these compounds produced moderate to low levels of catalepsy. Compound 9, with the
least binding affinity to the D2R, produced the least catalepsy and highest Minimum Adverse
Effective Dose (MAED) of the analogs tested regardless of their affinities at other receptors
including the 5-HT1AR. These observations support the hypothesis that moderation of the D2
binding of the tropane analogs could reduce catalepsy potential in rats and consequently EPS in
man.
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Haloperidol is an effective antipsychotic medication that is used to treat schizophrenia;
however, it is associated with producing short and long term extrapyramidal side effects
(EPS), i.e., Parkinsonism-like symptoms. These adverse effects may be due to its potent
binding at the D2 receptor and/or its metabolism into quaternary pyridinium species, such as
BCPP+ and RHPP+ 1,2,3,4 (Fig 1).
Previous studies in our laboratories have shown that modifications in the butyrophenone and
the piperidine moieties of haloperidol significantly altered its binding affinities at the D2,
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D4, and 5-HT1A receptors.1,5,4 Modifications of the piperidine ring resulting in D2 receptor
binding profiles that are similar or better than haloperidol and which could not form toxic
pyridinium metabolites, were also identified.4,6,7 These studies have indicated that adding an
ethylene bridge to the piperidine moiety to form a tropane analog, maintained or increased
affinity for the D2 receptor subtype. It was also observed that replacement of the carbonyl
functional group in haloperidol with an oxygen or a sulfur atom retains D2 binding and
increases affinity at the 5-HT1A receptor, indicating that the carbonyl group is not essential
for binding at the D2R but can be replaced with other groups to produce compounds that
bind with high affinity to the receptors associated with antipsychotic properties.8
While the tropane analog of haloperidol (5) appears to have a better binding profile than
haloperidol, in vivo studies in our hands have confirmed that its similar potent antagonism at
the D2R subtype resulted in very significant catalepsy in rats.5,9 Thus, it was of interest in
this study, to further test the hypothesis that moderation of the binding affinity at the D2
receptor could attenuate catalepsy in the tropane analogs of haloperidol. To test this
hypothesis, we modified the fluorobutyrophenone moiety while replacing the piperidinol
with 3-tropanol to obtain compounds 2-10 as shown in Fig 2 and then evaluated their
binding affinities at receptors associated with antipsychotic activity, i.e., D1 and D2-like
receptors, 5-HT1AR, 5-HT2AR and 5-HT7R (Table 1). Subsequently, binding affinities at
off-target receptors were also evaluated and reported in Table 2.
The syntheses of compounds 2-7 were previously reported.8–10 The alkylating agent, (3-
chloropropyl)(4-fluorophenyl)sulfane, was prepared using the procedure in our previously
published paper,8 with slight modification, by refluxing 4-fluorobenzenethiol and 1-
bromo-3-chloropropane in the presence of K2CO3 in iPrOH. The other two alkylating agents
were similarly prepared by using the corresponding n-fluorobenzenethiol. The target
compounds, 8-10 were obtained by alkylating 3-(4-chlorophenyl)-8-
azabicyclo[3.2.1]octan-3-ol, in the presence of K2CO3, KI and DME with the appropriate
alkylating agent as shown in Scheme 1.
The first modifications to moderate the D2R binding involve replacement of the carbonyl
group in haloperidol and the results are reported in Table 1. Deoxygenation (2), replacement
with oxygen (3) or sulfur (4) resulted in significant improvements in binding to the 5-HT1A,
D1 and D4 receptors. Affinity however, was decreased at the 5-HT7R while binding to the
D2 and 5-HT2A receptors remained about the same except for the deoxygenated compound
(2) which had a 27-fold decrease at the D2 receptor (Ki = 24 nM, haloperidol Ki = 0.89 nM).
The next compounds (5-8), the tropane analogs of haloperidol and compounds 2-4, were
also screened at the same receptors and the results are also presented in Table 1. The
methylene (6) and the oxygen (7) analogs had similar binding across all 7 receptors of
interest (Table 1); however, their affinities were significantly lower than those of the
previously reported carbonyl analog (5). The binding affinities of compound 8, the sulfur
analog of 6 and 7, turned out to be generally more potent at the primary receptors of interest,
i.e., D2, 5-HT1A, 5-HT2A and 5-HT7 receptors. Thus, compound 8 was selected for further
investigation.
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Having been aware that replacement of the fluorine atom on the butyrophenone moiety with
other substituents resulted in significant changes in binding affinities,8 we synthesized the
other two fluorinated analogs with the fluorine atom located at the meta (9) and the ortho
(10) positions on the butyrophenone moiety. The analogs were subsequently screened and
the results are recorded in Table 1. Compounds 8, 9 and 10 bind to the 5-HT1AR with
similar affinities (Ki = 20.0, 13.0 & 8.2 nM respectively) as expected. At the 5-HT2AR, the
binding Ki of the para- (8) and ortho- (10) substituted analogs were similar, and 4-6 times
more potent that of the meta-substituted analog (9). Apart from compound 8 which binds
with a Ki of 97.0 nM at the 5-HT7R, both 9 and 10 have about 9-fold weaker affinity. All
three analogs, 8-10, have potent binding at the D2-like receptors although the meta-
substituted analog, 9, displayed an 8-fold lower affinity (Ki = 27.0 nM) at the D2R subtype.
This D2 binding affinity turned out to be similar to that of the literature reported12 value for
olanzapine (Ki = 20.0 nM). Spurred on by this observation, (albeit superficial since the
binding studies were reported from different laboratories) and the potent binding to the 5-
HT1AR, purportedly associated with attenuating catalepsy in animal models,11 we selected
compounds 9 and 8 (for comparison) for evaluation in animal models predictive of
antipsychotic efficacy and EPS side effects.
The compounds were also evaluated for off-target interactions at receptors that may produce
side effects such as 5-HT2B, (valvular heart disease) 5-HT2C, (induction of weight gain), H1,
(induction of weight gain and/sedation) M1-M3, (cognitive symptoms) DAT, NET and
SERT which might interfere with in vivo observations. The results reported in Table 2,
indicate that all the compounds have relatively low affinities at these receptors and hence are
expected to have low potentials to induce weight gain, sedation and other potential side
effects associated with these receptors.13
To test for a compound's ability to display antipsychotic properties in humans, the inhibition
of apomorphine (APO)-induced climbing behavior in mice is evaluated.14,15 Thus, in this
study, the reversal of APO-induced climbing was assessed in Swiss Webster mice given 1.5
mg/kg of APO in a manner consistent with previous reports.1,5 Doses were expressed as the
free base for haloperidol and apomorphine, and as the HCl salt for compounds 8 and 9 and
were given in a volume of 10 mL/kg for the highest dose given by intraperitoneal (ip)
injection, except for APO, which was given by subcutaneous (sc) injection. Five mice were
each dosed, at various concentrations with compounds 8 or 9, then 30 min later with APO
(1.5 mg/kg). Each mouse was subsequently placed in a cylindrical wire cage to assess the
climbing behavior. Compound 8, the para-fluoro substituted analog had significant
inhibition of the APO-climbing behavior, with an ED50 value of 0.165 mg/kg (R2 = 0.9511)
compared to its meta-substituted counterpart, 9 (ED50 = 3.137 mg/kg; R2 = 0.9132). These
results are consistent with the fact that the para analog is more potent than the meta analog
and possesses APO-induced climbing reversal properties similar to haloperidol (ED50 =
0.122 mg/kg) as expected, while 9 is less potent at the D2 receptor and displayed an equally
lower potency in the in vivo model. The results are reported in Fig. 3 and Table 3.
The potential for compounds 8 and 9 to induce catalepsy in rats and hence extrapyramidal
side effects in human beings16,11 was also assessed using the catalepsy bar test as previously
reported.17,18 A secondary evaluation was also made using the crossed-legs position (CLP)
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test, which is reported to be more sensitive to the anticataleptic actions of 5-HT1A receptor
agonists.19,11 Five rats at each dose point, for 8 (ED50-9 ED50) or 9 (ED50-5 ED50), were
injected i.p. and tested in the CLP test for 30 sec followed by the bar test for 30 sec. A
righting test20,21 was performed immediately after, to assess the potential of the compounds
to induce sedation. This was repeated at 3 and 6 minutes after the start of the first trial. The
mean of the three trials was used. The results are reported in Fig. 3 and Table 3.
Compound 8 induced catalepsy in both the bar and CLP tests. One-way ANOVA with
Bonferroni post tests with p<0.05 indicated that there was a significant difference between
vehicle (1% lactic acid) and compound 8. The Minimum Adverse Effective Dose (MAED)
for the bar test was observed at 0.578 mg/kg or 3.5 times its ED50 value for reversal of
APO-induced climbing behavior. Since all animals “righted” themselves after the catalepsy
tests, catalepsy displayed by compound 8 was not associated with a sedative effect by the
compound, which is consistent with its poor binding at the 5-HT2C and H1 receptors (Ki =
1498 & 977 nM respectively; Table 2). Compound 9 also demonstrated catalepsy with a
MAED of 12.7 mg/kg or 4.0 times the ED50 of its reversal of APO-induced climbing
behavior. Given that the MAED of haloperidol was only 2.0 times its ED50 value of reversal
of the APO-induced climbing behavior, the observed trend supports the hypothesis that
potent binding at the D2 receptor is associated with the potential of a compound to induce
catalepsy and that its moderation would result in attenuation of catalepsy induction.
In conclusion, initial modifications of haloperidol have produced analogs with antipsychotic
potential as demonstrated by inhibition of apomorphine-induced climbing behavior.
Catalepsy testing revealed that a tropane analog with potent binding to the D2 receptor, still
had potent catalepsy, suggesting that binding to the D2R plays a key role in EPS in humans.
Further modifications of the tropane analog produced compounds with relatively lower
binding affinities to the D2 receptor compared to haloperidol. While haloperidol produced
maximum catalepsy, these compounds produced moderate to low levels of catalepsy.
Compound 9, with the least binding to the D2R, produced the least catalepsy and the highest
MAED of the analogs tested even though the Ki values for the 5-HT1AR were similar and
moderately potent. These observations are consistent with the hypothesis that further
moderation of the binding affinity of the tropane analogs at the D2R, would attenuate their
catalepsy potential in rats.
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Quaternary Pyridinium Metabolites of Haloperidol
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Structures of Compounds Evaluated
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Inhibition of APO-induced climbing behavior in Swiss-Webster mice, n=5/dose, by
Compound 8, Compound 9, and haloperidol in graph 1A, 1D, and 1G respectively. Mean
time in seconds on the bar or in the CLP stance for Sprague-Dawley rats, n=5. Graphs 1B
and 1C are compound 8. Graphs 2E and 2F are compound 9. Graphs 2H and 2I are
haloperidol. Significant difference between vehicle and dose of compound indicated by *
(p<0.05), *** (p<0.001), and **** (p<0.0001).
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Reagents: (i) iPrOH, K2CO3, reflux 12 h; (ii) 3-(4-chlorophenyl)-8-
azabicyclo[3.2.1]octan-3-ol (B), DME, KI, K2CO3, 100 °C, reflux, 12 h.
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